Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3731319 | 0.97 | LIPE (0.39) | LIPEPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL31509818 | 0.91 | LIPE (0.40) | LIPEPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3739276 | 0.91 | LIPE (0.40) | LIPEPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22034964 | 0.87 | PDE4A (0.46) | LIPEPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3747007 | 0.83 | NR1H2 (0.43) | LIPENR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL30326282 | 0.83 | NR1H2 (0.43) | LIPENR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL24510440 | 0.81 | LIPE (0.44) | LIPEEPHX1NR1H2HPGDGPR119 | |
| SCHEMBL3744055 | 0.79 | EPHX1 (0.40) | PDE4APDE4BPDE4CPDE4DEPHX1 | |
| SCHEMBL17925891 | 0.79 | USP2 (0.38) | LIPENR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL20531880 | 0.78 | CHRNB2 (0.38) | LIPENR1H2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242285-B2 | N-tert-butoxycarbonyl-2-pyrrolidinones and production method thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20100280259-A1 | N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20090281331-A1 | METHOD OF PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDITION SALT THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090163722-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| EP-2014648-A1 | PROCESS FOR PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDUCT SALT THEREOF | Sumitomo Chemical Company, Limited (JP) | 2009-01-14 | — | — | EP | disclosed |
| EP-2008999-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PROCESS FOR PRODUCING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2008-12-31 | — | — | EP | disclosed |
| EP-1615886-A1 | [C]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS | Warner-Lambert Company LLC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050250800-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN S | 2005-11-10 | — | — | US | disclosed |
| US-20050137215-A1 | [C]-fused bicyclic proline derivatives and their use for treating arthritic conditions | GUZZO PETER R (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2004092134-A1 | [C]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20030119858-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2003-06-26 | — | — | US | disclosed |
| US-6489352-B2 | ANTIEPILEPTIC AGENTS; NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY | 2002-12-03 | — | — | US | disclosed |
| US-20020019540-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2002-02-14 | — | — | US | disclosed |
| US-6316638-B1 | FOR THERAPY OF EPILEPSY, FAINTNESS ATTACKS, HYPOKINESIA, CRANIAL DISORDERS, NEURODEGENERATIVE DISORDERS, DEPRESSION, ANXIETY, PANIC, PAIN, AND NEUROPATHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY | 2001-11-13 | — | — | US | disclosed |
| EP-1082306-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999061424-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281331-A1 | METHOD OF PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDITION SALT THEREOF | C9, NPPA, ADH1C | LIPE 4827/4885PDE4A 2985/4885PDE4B 3158/4885 |
| US-20050250800-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, GABRA6, GABRA2 | LIPE 3495/4885PDE4A 560/4885PDE4B 424/4885 |
| US-20020019540-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, SLC18A1, CDR2 | LIPE 4004/4885PDE4A 672/4885PDE4B 579/4885 |
| US-20090163722-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF | TERT, CBR1, TELO2 | LIPE 3480/4885PDE4A 4686/4885PDE4B 4683/4885 |
| US-20030119858-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, SLC18A1, CDR2 | LIPE 4004/4885PDE4A 672/4885PDE4B 579/4885 |
| US-20100280259-A1 | N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof | TERT, CBR1, TELO2 | LIPE 3480/4885PDE4A 4686/4885PDE4B 4683/4885 |
| US-20050137215-A1 | [C]-fused bicyclic proline derivatives and their use for treating arthritic conditions | PPIC, PRAP1, PRRC2C | LIPE 4578/4885PDE4A 2327/4885PDE4B 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.